Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria

NCT00104260 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

Phenylketonurias

Interventions

DRUG: sapropterin dihydrochloride

Sponsor

BioMarin Pharmaceutical